Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vicore Pharma Holding AB ( (SE:VICO) ) has shared an announcement.
Vicore Pharma Holding AB has released its interim report for the first quarter of 2026, covering the period from January 1 to March 31. The report outlines CEO commentary, pipeline status, financial information, sustainability efforts, and key performance measures for the group and parent company.
The disclosure signals continued operational transparency and provides stakeholders with an overview of Vicore’s financial health, development pipeline, and sustainability priorities during the quarter. It also offers context on how the company is managing its resources and positioning itself for future progress within its target therapeutic areas.
The most recent analyst rating on (SE:VICO) stock is a Buy with a SEK38.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a publicly listed biopharmaceutical company focused on developing innovative therapies in the life sciences sector. The company operates through a research-driven pipeline and targets unmet medical needs, positioning itself within specialized pharmaceutical markets.
Average Trading Volume: 520,577
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.81B
For a thorough assessment of VICO stock, go to TipRanks’ Stock Analysis page.